Last reviewed · How we verify
Magnesium Esomeprazole
Magnesium Esomeprazole is a Proton pump inhibitor (PPI) Small molecule drug developed by Takeda. It is currently FDA-approved for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.
Magnesium esomeprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion.
Magnesium esomeprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.
At a glance
| Generic name | Magnesium Esomeprazole |
|---|---|
| Sponsor | Takeda |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Esomeprazole is the active S-enantiomer of omeprazole that irreversibly binds to and inhibits the H+/K+-ATPase enzyme (proton pump) on the secretory surface of gastric parietal cells. This blocks the final step of gastric acid production, significantly reducing intragastric acidity. The magnesium salt formulation improves solubility and bioavailability compared to the free base.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Zollinger-Ellison syndrome
- Prevention of NSAID-induced ulcers
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Constipation
- Hypomagnesemia (with long-term use)
Key clinical trials
- Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing (PHASE4)
- Drug Interaction Study on Linaprazan Glurate Capsules (PHASE1)
- Study Comparing Esomeprazole Associated With Sodium Bicarbonate From Eurofarma and Esomeprazole in Treatment of Gastroesophageal Reflux Disease ESOBIC (PHASE3)
- A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis (PHASE3)
- Furazolidone Quadruple Regimen Eradicate H. Pylori Infection (PHASE1, PHASE2)
- A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA) (PHASE4)
- Esomeprazole Magnesium Dihydrate 40 mg Tablets Relative to Nexium 40 mg Tablets Under Fasting Condition (PHASE1)
- Esomeprazole Magnesium Dihydrate 40 mg Tablets Relative to Nexium 40 mg Tablets Under Fed Condition (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Magnesium Esomeprazole CI brief — competitive landscape report
- Magnesium Esomeprazole updates RSS · CI watch RSS
- Takeda portfolio CI
Frequently asked questions about Magnesium Esomeprazole
What is Magnesium Esomeprazole?
How does Magnesium Esomeprazole work?
What is Magnesium Esomeprazole used for?
Who makes Magnesium Esomeprazole?
What drug class is Magnesium Esomeprazole in?
What development phase is Magnesium Esomeprazole in?
What are the side effects of Magnesium Esomeprazole?
What does Magnesium Esomeprazole target?
Related
- Drug class: All Proton pump inhibitor (PPI) drugs
- Target: All drugs targeting H+/K+-ATPase (proton pump)
- Manufacturer: Takeda — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Indication: Drugs for Gastroesophageal reflux disease (GERD)
- Indication: Drugs for Peptic ulcer disease
- Indication: Drugs for Zollinger-Ellison syndrome
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing